Research conducted by Innovent Biologics Inc. has shown that IL-2Rα-biased agonists, compared to IL-2Rβγ-biased agonists, significantly enhance tumor-specific CD8+ T cells (TSTs), demonstrating a superior antitumor efficacy. This evidence concerns the gene CD8A and neoplasm.